CJC-1295 isn't stocked on pharmacy shelves in Zeri or most other cities — it's a research-grade peptide available through a dedicated online market. The key implication for Zeri researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the quality verification approach is identical for researchers everywhere. Separating genuine research-grade CJC-1295 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the framework here are universal across all research contexts.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Zeri comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors begins with the COA: locate the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Strong quality indicators beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Zeri
COA-verified · International tracking · Research grade
All use of CJC-1295 in Zeri or anywhere is research use only — this compound is not approved for clinical human use, and all handling should follow research laboratory protocols. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
